{"doi":"10.1002/art.42661","title":"Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (<scp>PRESTO</scp>): A Step Towards Prevention","abstract":"<jats:sec><jats:title>Objective</jats:title><jats:p>A simple, scalable tool that identifies psoriasis patients at high risk for developing psoriatic arthritis (PsA) could improve early diagnosis. We aimed to develop a risk prediction model for the development of PsA and to assess its performance among patients with psoriasis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We analyzed data from a prospective cohort of psoriasis patients without PsA at enrollment. Participants were assessed annually by a rheumatologist for the development of PsA. Information about their demographics, psoriasis characteristics, comorbidities, medications, and musculoskeletal symptoms was used to develop prediction models for PsA. Penalized binary regression models were used for variable selection while adjusting for psoriasis duration. Risks of developing PsA over 1‐ and 5‐year time periods were estimated. Model performance was assessed by the area under the curve (AUC) and calibration plots.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among 635 psoriasis patients, 51 and 71 developed PsA during the 1‐year and 5‐year follow‐up periods, respectively. The risk of developing PsA within 1 year was associated with younger age, male sex, family history of psoriasis, back stiffness, nail pitting, joint stiffness, use of biologic medications, patient global health, and pain severity (AUC 72.3). The risk of developing PsA within 5 years was associated with morning stiffness, psoriatic nail lesion, psoriasis severity, fatigue, pain, and use of systemic nonbiologic medication or phototherapy (AUC 74.9). Calibration plots showed reasonable agreement between predicted and observed probabilities.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients using readily available clinical variables.</jats:p><jats:p><jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" mimetype=\"image/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic/art42661-toc-0001-m.png\"><jats:alt-text>image</jats:alt-text></jats:graphic></jats:boxed-text></jats:p></jats:sec>","journal":"Arthritis &amp; Rheumatology","year":2025,"id":640492,"datarank":0.519860385419959,"base_score":3.4657359027997265,"endowment":3.4657359027997265,"self_citation_contribution":0.519860385419959,"citation_network_contribution":0.0,"self_endowment_contribution":0.519860385419959,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":31,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1664611,"name":"Ker‐Ai Lee","orcid":null,"position":1,"is_corresponding":false},{"id":660188,"name":"Vinod Chandran","orcid":"0000-0002-8297-0275","position":2,"is_corresponding":false},{"id":1664612,"name":"Jessica Widdifield","orcid":"0000-0002-7464-0460","position":3,"is_corresponding":false},{"id":453637,"name":"Aaron M. Drucker","orcid":"0000-0002-7388-9475","position":4,"is_corresponding":false},{"id":226250,"name":"Christopher T. Ritchlin","orcid":"0000-0002-2602-1219","position":5,"is_corresponding":false},{"id":660189,"name":"Cheryl F. Rosen","orcid":"0000-0002-5807-0445","position":6,"is_corresponding":false},{"id":1664613,"name":"Richard J. Cook","orcid":null,"position":7,"is_corresponding":false},{"id":298582,"name":"Dafna D. Gladman","orcid":"0000-0002-9074-0592","position":8,"is_corresponding":false},{"id":408498,"name":"Lihi Eder","orcid":"0000-0002-1473-1715","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (<scp>PRESTO</scp>): A Step Towards Prevention","abstract":"<jats:sec><jats:title>Objective</jats:title><jats:p>A simple, scalable tool that identifies psoriasis patients at high risk for developing psoriatic arthritis (PsA) could improve early diagnosis. We aimed to develop a risk prediction model for the development of PsA and to assess its performance among patients with psoriasis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We analyzed data from a prospective cohort of psoriasis patients without PsA at enrollment. Participants were assessed annually by a rheumatologist for the development of PsA. Information about their demographics, psoriasis characteristics, comorbidities, medications, and musculoskeletal symptoms was used to develop prediction models for PsA. Penalized binary regression models were used for variable selection while adjusting for psoriasis duration. Risks of developing PsA over 1‐ and 5‐year time periods were estimated. Model performance was assessed by the area under the curve (AUC) and calibration plots.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among 635 psoriasis patients, 51 and 71 developed PsA during the 1‐year and 5‐year follow‐up periods, respectively. The risk of developing PsA within 1 year was associated with younger age, male sex, family history of psoriasis, back stiffness, nail pitting, joint stiffness, use of biologic medications, patient global health, and pain severity (AUC 72.3). The risk of developing PsA within 5 years was associated with morning stiffness, psoriatic nail lesion, psoriasis severity, fatigue, pain, and use of systemic nonbiologic medication or phototherapy (AUC 74.9). Calibration plots showed reasonable agreement between predicted and observed probabilities.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients using readily available clinical variables.</jats:p><jats:p><jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" mimetype=\"image/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic/art42661-toc-0001-m.png\"><jats:alt-text>image</jats:alt-text></jats:graphic></jats:boxed-text></jats:p></jats:sec>","is_dataset_classified":null,"base_score":3.4657359027997265,"endowment":3.4657359027997265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37555242","pmcid":"PMC12123250","openalex_id":"https://openalex.org/W4385683981","authors":[],"funders":[{"funder_name":"Pfizer Chair Research Award, Rheumatology, University of Toronto","grant_id":"","title":null},{"funder_name":"Krembil Foundation","grant_id":"","title":null},{"funder_name":"Canada Research Chair in Inflammatory Rheumatic Diseases (Tier 2)","grant_id":"","title":null},{"funder_name":"New Investigator Grant from the Physician Services Incorporated (PSI) Foundation","grant_id":"","title":null}],"total_grants":4,"fwci":5.8506,"citation_percentile":0.97174298,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":12},{"year":2025,"count":10},{"year":2026,"count":8}],"oa_status":"hybrid","license":"cc-by-nc","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.42661","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.42661","host_type":"publisher"},{"url":"https://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/art.42661","host_type":"publisher"},{"url":"https://doi.org/10.1002/art.42661","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37555242","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12123250","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12123250/pdf/ART-77-686.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12123250","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12123250?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Spondyloarthritis Studies and Treatments","Psoriasis: Treatment and Pathogenesis","Rheumatoid Arthritis Research and Therapies"],"mesh_terms":["Adult","Age Factors","Aged","Female","Humans","Male","Middle Aged","Prospective Studies","Psoriasis","Risk Factors","Severity of Illness Index","Sex Factors","Arthritis, Psoriatic","Risk Assessment"],"keywords":["Medicine","Psoriasis","Psoriatic arthritis","Cohort","Internal medicine","Psoriasis Area and Severity Index","Physical therapy","Dermatology"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T12:16:59.965749Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}